I give management a passing grade of b+DYOR and read the...

I give management a passing grade of b+

DYOR and read the announcements they’ve done plenty, and by that I mean plenty. Even today’s quarterly had loads of sales activities going on…..I’m not going to list them all.

Trials, new module fda coming up, signing Thermo Fisher, Thermo Fisher product launch with 2022 sales targets….the list goes on….all while a pandemic is still surging in the states blocking up access.

And I can’t be any clearer, if I thought they deserved a failing grade I’d sell my holding and be on my my way.

Why would I hold a position in a med tech specie that’s just really started it’s commercialisation phase if I thought management was failing.

This isn’t some established large cap behemoth.

The current price is meaningless except to point out this hasn’t broke out of the small circle of retail investors.

Only sales are going to do that, and IMO they’re coming baby.

GLTAH

50 bags in fifty years or bust